View Post

Immunomedics Announces Publication of Triple-Negative Breast Cancer Data With Sacituzumab Govitecan in the New England Journal of Medicine

In Clinical Trials by Barbara Jacoby

Source: Immunomedics From: globenewswire.com Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that updated data from the Phase 2 study of sacituzumab govitecan in patients with metastatic triple-negative breast cancer (mTNBC) were published on NEJM.org as part of the February 21 print issue of the New England …

View Post

Compound Found in Olives May Help Prevent Deadly Type of Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Rosa Gonzalez-Lamas From: oliveoiltimes.com A chemical found in both olives and extra virgin olive oil may be useful as an alternative therapy for the prevention of triple-negative breast cancer, according to research conducted by Spain’s University of Jaén. The researchers have confirmed the chemopreventive properties that hydroxytyrosol might have in the treatment of this disease. Hydroxytyrosol is a type …

View Post

PrimeVax Immuno-Oncology Receives IND Permission From FDA

In Clinical Trials by Barbara Jacoby

Source: PrimeVax Immuno-Oncology, Inc. From: prnewswire.com PrimeVax Immuno-Oncology, Inc. announced today that the company has successfully received their Investigational New Drug (IND) Application permission from the FDA to begin running their first human clinical trial. “Our goal is simple: treat melanoma patients who have exhausted their options,” states Tony Chen, PrimeVax’s CEO. “It has been a long road, but we …

View Post

Researchers identify potential target for new breast cancer treatments

In In The News by Barbara Jacoby

Source: https://www.kcl.ac.uk From: news-medical.net Researchers from the School of Basic & Medical Biosciences have identified a potential target that could lead to new treatments for triple negative breast cancer. One in five patients with breast cancer are diagnosed with triple negative breast cancer, a cancer type where tumour cells don’t have receptors for oestrogen and progesterone, or the Her2 protein. …

View Post

CytRx Corporation Highlights Aldoxorubicin Included in New NantCell Inc. Triple Negative Breast Cancer Clinical Trial

In Clinical Trials by Barbara Jacoby

News provided by: CytRx Corporation From: prnewswire.com This New Trial Represents the Third NantCell Study Evaluating Aldoxorubicin Combined with Immunotherapy or Cell-Based Therapy CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has dosed the first patient in the Phase 1b portion of a …

View Post

CAR-T Trial for Triple-Negative Breast Cancer Under Way

In Clinical Trials by Barbara Jacoby

By: Christina Bennett, MS From: cancertherapyadvisor.com A phase 1 trial (ClinicalTrials.gov Identifier: NCT02706392) is underway at Fred Hutchinson Cancer Research Center to evaluate a chimeric antigen receptor (CAR) T cell therapy in patients with cancer who have receptor tyrosine kinase-like orphan receptor 1 (ROR1)-positive disease, including those with triple-negative breast cancer (TNBC). The trial progress and early data for patients …

View Post

New Clinical Trial for Triple-Negative Breast Cancer at Sylvester Comprehensive Cancer Center

In Clinical Trials by Barbara Jacoby

Vaccine Designed to Prevent Recurrence Panic washed over Jackie Barrett when she first received her breast cancer diagnosis. “My eyes went dark. I couldn’t hear anything. It was like a train was coming at me,” she says. Jackie’s oncologist explained that her type of breast cancer is called triple-negative because it does not have receptors for estrogen, progesterone or the …

View Post

Norwalk Hospital reports positive results with breast cancer clinical trials

In Clinical Trials by Barbara Jacoby

By: Kevin Zimmerman From: westfaironline.com Four cutting-edge breast cancer clinical trials recently launched at Norwalk Hospital’s C. Anthony and Jean Whittingham Cancer Center are giving hope to patients diagnosed with triple negative breast cancer, an aggressive form of the disease that cannot be treated with hormone therapies or other cancer-fighting drugs. “We started about six months ago,” said Dr. Linda …